Recently TauRx Pharma presented data from their phase 3 clinical studies on a new TAU Aggregation inhibitor.
Co-founder of TAURx Pharma and Professor at Institute of Pharmacology at Charite, Franz Theuring, will share data from this study and give an insight to the some of the latest advancements in the field of Alzheimer’s disease treatment.
Sign up to attend at 亚博娱乐官网_亚博pt手机客户端登录sparken
Programme
13:00 –13:05: Welcome by Morten Egeberg (Leader Spark Norway) and Bjarte Reve (CEO Nansen Neuroscience Network)
13:05 –14:00: Lecture by Professor Franz Theuring
14:00 –14:30: Refreshment and networking
Abstract
Alzheimer’s disease (AD) is a complex and heterogenous neurodegenerative disease of the CNS, first presented 1907 by Alois Alzheimer, a German psychiatrist. It represents the most prevalent of the group of tauopathies, a diverse group of neurodegenerative disorders associated with cognitive and behavioural impairment in the ageing population. AD is characterised by the deposition of extracellular ?-amyloid plaques and intracellular tau neurofibrillary tangles (NFTs).
There is an urgent need for a disease-modifying treatment for AD. For the last 35 years the Pharma industry has focused on the development of drugs fighting AD on the basis of the amyloid hypothesis, whereby the formation of extracellular plaques play the major role in the disease process. However, we focus on the development of an orally administered tau protein aggregation inhibitor (TAI), hydromethylthionine mesylate (HMTM) to treat AD. NFTs and their constituent paired helical filaments (PHFs) are abnormal accumulations of aberrantly folded microtubule-associated protein tau. HMTM is a stable reduced crystalline form of methylthioninium (MT) that acts as a TAI. In tau transgenic mouse models HMTM reduced the tau pathology and behavioural impairment of the animals. It acts both by inhibiting tau aggregation and by disaggregating pathological tau oligomers and filaments.
Data on the preclinical and clinical phases (phase 2 and phase 3 clinical trials) on the development of HMTM will be presented.
About
Professor Franz Theuring, PhD, studied electronics and biology at the Universities of Brauschweig and Goettingen, Germany. He gained his PhD in 1986 in the Institute of Human Genetics, University of Goettingen, and was post-doctoral research fellow at the Max Planck Institute for Biophysical Chemistry under Professor Peter Gruss. Professor Theuring was responsible for the establishment and introduction of transgenic technologies both in the Gruss laboratory, and then from 1988 in the Institute of Cellular and Molecular Biology of Schering AG, Berlin, where he had responsibility for implementation of transgenic technologies in areas of pharmacological research for drug target validation and model development at Schering.
Professor Theuring received his Habilitation from the Free University of Berlin in Molecular Biology and Biochemistry in 1996, and after 8 years at Schering AG, was appointed in 1996 to a Professorship in Molecular Pharmacology at the Charité – Universitaetsmedizin Berlin.
Prof. Theuring is an acknowledged expert in employing transgenic technologies in biomedicine. He is consultant to the Berlin State in Biotechnology, to the European Union in Molecular Medicine and to Pharmaceutical Industry. He was elected as Member of the Berlin Scientific Society (BWG) and acted as the President from 2014-2017.
In 2000, he spent 3.5 month on a sabbatical leave at the Centre for Animal Resources and Development (CARD) at Kumamoto University, Japan. Furthermore, he is the co-founder of two biotech companies, Proteome Factory, based in Berlin, and TauRx Pharma, based in Singapore. Since 2015 Prof. Theuring is engaged in activities of SPARK-BIH Berlin, an academic initiative to accelerate breakthrough findings into medicines, diagnostics and medical devices. Since 2020 he’s acting as one of the two directors of the SPARK initiative.
Link to TauRx Pharma
